Skip to main content
A

ADIMMUNE CORPORATION — Investor Relations & Filings

Ticker · 4142 LEI · 549300M5TV8YGVXU1827 TW Manufacturing
Open in API
Filings indexed 1,793 across all filing types
Latest filing 2026-04-29 Regulatory Filings
Country TW Taiwan
Listing TW 4142

About ADIMMUNE CORPORATION

http://www.adimmune.com.tw/

ADIMMUNE CORPORATION, established in 1965, specializes in the research, development, and large-scale manufacturing of human vaccines and biologics. The company is a primary supplier of seasonal influenza and tetanus vaccines, maintaining production facilities that adhere to PIC/S GMP, US FDA, and EU standards. Its operations encompass the full product lifecycle, from initial R&D to commercial distribution. In addition to its proprietary vaccine portfolio, the company provides Contract Development and Manufacturing Organization (CDMO) services, supporting collaborative development and global supply chains. Recognized for its technical expertise in viral and bacterial vaccine production, the organization focuses on delivering high-quality immunization solutions to international markets while leveraging its history as a pioneering vaccine laboratory.

Recent filings

Filing Released Lang Actions
115年年報及股東會資料 — 2026_4142_20260604FE2.pdf
Regulatory Filings
2026-04-29 English
115年年報及股東會資料 — 2026_4142_20260604F13.pdf
Regulatory Filings
2026-04-29 Chinese
115年年報及股東會資料 — 2026_4142_20260604F02.pdf
Regulatory Filings
2026-04-29 Chinese
115年年報及股東會資料 — 2026_4142_20260604FE1.pdf
AGM Information Classification · 1% confidence The document is titled “Annual General Shareholders' Meeting Notice” and outlines the date, time, location, and detailed agenda items for the upcoming physical AGM. It does not present financial results, nor is it a quarterly or annual report; rather, it is a notification and agenda for the AGM itself. This aligns with the AGM Information category (AGM-R).
2026-04-29 English
115年年報及股東會資料 — 2026_4142_20260604F01.pdf
Proxy Solicitation & Information Statement Classification · 1% confidence The document is clearly the formal notice of the company’s 2026 Annual General Meeting to shareholders, including an agenda, voting and proxy‐solicitation instructions, proxy form and list of solicitors. It is not the financial report itself but the proxy solicitation and informational statement sent out to request votes. This matches the “Proxy Solicitation & Information Statement” category (PSI).
2026-04-29 Chinese
公司基本資料
Fund Information / Factsheet Classification · 1% confidence The document is a concise corporate profile from Taiwan’s Public Information Observatory listing stock code, industry, addresses, board members, capital, listing dates, IR contacts, and basic corporate governance links. It serves as a brief factsheet of key company information rather than a full financial report or an announcement of a specific event. This fits the definition of a Fund Information / Factsheet (FS).
2026-04-23 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.